Fenoget Capsules 67Mg
Brand : getz pharma pakistan
Requires Prescription (YES/NO)
How it works
Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type alpha (PPARa). Through activation of PPARa, fenofibrate increases the lipolysis and elimination of atherogenic triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein CIII. Activation ofPPARa also induces an increase in the synthesis of apoproteins AI and AII. The above stated effects of fenofibrate on lipoproteins lead to a reduction in very low and low density fractions (VLDL and LDL) containing apoprotein B and an increase in the high density lipoprotein fraction (HDL) containing apoprotein AI and AII. In addition, through modulation of the synthesis and the catabolism of VLDL fractions fenofibrate increases the LDL clearance and reduces small dense LDL, the levels of which are elevated in the atherogenic lipoprotein phenotype, a common disorder in patients at risk for coronary heart disease.
USAGE AND SAFETY
Common: Abdominal pain, nausea, vomiting, diarrhea, flatulence and transaminases increased. Uncommon: Headache, pulmonary embolism, deep vein thrombosis, pancreatitis, cholelithiasis, cutaneous hypersensitivity (e.g. rashes, pruritus, urticaria) and muscle disorder (e.g. myalgia, myositis, muscular spasms and weakness). Rare: Hemoglobin decreased, white blood cell count decreased, hypersensitivity,hepatitis, alopecia and photosensitivity reactions .
Oral Anticoagulants , HMG-CoA Reductase Inhibitors (Statins) , Resins , Cyclosporine , Beta-blockers, thiazides, estrogens , Daptomycin , Antidiabetics , Colchicine .
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.
When not to Use
Fenofibrate is contraindicated in patients: - With hypersensitivity to fenofibrate or any component of the product. - With severe renal dysfunction. - With hepatic dysfunction, including primary biliary cirrhosis and unexplained persistent liver function abnormality. - With pre-existing gall bladder disease. - With chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia. - Fenofibrate should not be used in nursing mothers.
Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with fenofibrate. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities .
Regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with fenofibrate, and therapy should be discontinued if enzyme levels persist above three times the normal limit .
Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gall bladder studies are indicated and fenofibrate therapy should be discontinued if gallstones are found .
Patients receiving fenofibrate and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy, including serum creatinine kinase level determination. If myopathy/myositis is suspected or diagnosed, fenofibrate therapy should be stopped.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.